June 28, 2024 03:33 PM EDT

Merck calls ACIP's pneumococcal recommendation a 'missed opportunity,' advocates for expanding age group

Nicole DeFeudis

Editor

The CDC’s Advisory Committee on Immunization Practices (ACIP) has recommended Merck’s recently approved 21-valent pneumococcal vaccine Capvaxive for adults 65 years …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck calls ACIP's pneumococcal recommendation a 'missed opportunity,' advocates for expanding age group

Nicole DeFeudis

Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Merck calls ACIP's pneumococcal recommendation a 'missed opportunity,' advocates for expanding age group

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs